These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 22767342)

  • 1. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America.
    Genberg BL; Wilson IB; Bangsberg DR; Arnsten J; Goggin K; Remien RH; Simoni J; Gross R; Reynolds N; Rosen M; Liu H;
    AIDS; 2012 Jul; 26(11):1415-23. PubMed ID: 22767342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS.
    Hirsch JD; Gonzales M; Rosenquist A; Miller TA; Gilmer TP; Best BM
    J Manag Care Pharm; 2011 Apr; 17(3):213-23. PubMed ID: 21434698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved adherence to modern antiretroviral therapy among HIV-infected injecting drug users.
    Mann B; Milloy MJ; Kerr T; Zhang R; Montaner J; Wood E
    HIV Med; 2012 Nov; 13(10):596-601. PubMed ID: 22551168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
    Sutton SS; Magagnoli J; Hardin JW
    Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alcohol Use and Antiretroviral Therapy Non-Adherence Among Adults Living with HIV/AIDS in Sub-Saharan Africa: A Systematic Review and Meta-Analysis.
    Velloza J; Kemp CG; Aunon FM; Ramaiya MK; Creegan E; Simoni JM
    AIDS Behav; 2020 Jun; 24(6):1727-1742. PubMed ID: 31673913
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels.
    Parienti JJ; Das-Douglas M; Massari V; Guzman D; Deeks SG; Verdon R; Bangsberg DR
    PLoS One; 2008 Jul; 3(7):e2783. PubMed ID: 18665246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.
    Gandhi M; Ameli N; Bacchetti P; Anastos K; Gange SJ; Minkoff H; Young M; Milam J; Cohen MH; Sharp GB; Huang Y; Greenblatt RM
    Clin Infect Dis; 2011 May; 52(10):1267-75. PubMed ID: 21507924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.
    Lester RT; Ritvo P; Mills EJ; Kariri A; Karanja S; Chung MH; Jack W; Habyarimana J; Sadatsafavi M; Najafzadeh M; Marra CA; Estambale B; Ngugi E; Ball TB; Thabane L; Gelmon LJ; Kimani J; Ackers M; Plummer FA
    Lancet; 2010 Nov; 376(9755):1838-45. PubMed ID: 21071074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
    Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
    HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda.
    Oyugi JH; Byakika-Tusiime J; Ragland K; Laeyendecker O; Mugerwa R; Kityo C; Mugyenyi P; Quinn TC; Bangsberg DR
    AIDS; 2007 May; 21(8):965-71. PubMed ID: 17457090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-Infected Ugandan Women on Antiretroviral Therapy Maintain HIV-1 RNA Suppression Across Periconception, Pregnancy, and Postpartum Periods.
    Matthews LT; Ribaudo HB; Kaida A; Bennett K; Musinguzi N; Siedner MJ; Kabakyenga J; Hunt PW; Martin JN; Boum Y; Haberer JE; Bangsberg DR
    J Acquir Immune Defic Syndr; 2016 Apr; 71(4):399-406. PubMed ID: 26495883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a Canadian setting.
    Nolan S; Milloy MJ; Zhang R; Kerr T; Hogg RS; Montaner JS; Wood E
    AIDS Care; 2011 Aug; 23(8):980-7. PubMed ID: 21480010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil.
    Teixeira C; Dourado Mde L; Santos MP; Brites C
    AIDS Res Hum Retroviruses; 2013 May; 29(5):799-804. PubMed ID: 23294471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
    Shet A; Kumarasamy N; Poongulali S; Shastri S; Kumar DS; Rewari BB; Arumugam K; Antony J; De Costa A; D'Souza G
    Curr HIV Res; 2016; 14(1):71-9. PubMed ID: 26303008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.
    Nieuwkerk PT; Sprangers MA; Burger DM; Hoetelmans RM; Hugen PW; Danner SA; van Der Ende ME; Schneider MM; Schrey G; Meenhorst PL; Sprenger HG; Kauffmann RH; Jambroes M; Chesney MA; de Wolf F; Lange JM;
    Arch Intern Med; 2001 Sep; 161(16):1962-8. PubMed ID: 11525698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the first year of a pilot program in community pharmacy: HIV/AIDS medication therapy management for Medi-Cal beneficiaries.
    Hirsch JD; Rosenquist A; Best BM; Miller TA; Gilmer TP
    J Manag Care Pharm; 2009; 15(1):32-41. PubMed ID: 19125548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy.
    O'Connor JL; Gardner EM; Esser S; Mannheimer SB; Lifson AR; Telzak EE; Phillips AN;
    HIV Med; 2016 Feb; 17(2):124-32. PubMed ID: 26186609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adherence to antiretroviral therapy and the associated factors among people living with HIV/AIDS in Northern Peru: a cross-sectional study.
    Leyva-Moral JM; Loayza-Enriquez BK; Palmieri PA; Guevara-Vasquez GM; Elias-Bravo UE; Edwards JE; Feijoo-Cid M; Davila-Olano LY; Rodriguez-Llanos JR; Leon-Jimenez FE
    AIDS Res Ther; 2019 Aug; 16(1):22. PubMed ID: 31462291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.